Expert oncologists center discussion on a clinical scenario to highlight optimal treatment strategies in metastatic triple-negative breast cancer.
EP. 1: Perspectives on the Current Treatment Landscape of TNBC
Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.
EP. 2: Clinical Scenario: mTNBC Treated With Chemotherapy Then Sacituzumab Govitecan
After reviewing a patient scenario of relapsed/refractory metastatic TNBC, expert oncologists elucidate use of sacituzumab govitecan in this setting.
EP. 3: Metastatic TNBC: Safety, Efficacy, and Quality of Life With Sacituzumab Govitecan
Comprehensive discussion on the safety and efficacy profile of the antibody-drug conjugate (ADC) sacituzumab govitecan and managing ADC-related adverse events in patients with mTNBC.
EP. 4: Novel ADCs Under Investigation in Triple-Negative Breast Cancer
Expert oncologists review novel ADCs in TNBC and consider how their approval may impact sequencing of therapy in this setting.
EP. 5: Addressing Unmet Needs in the Management of TNBC
Perspectives on the most prominent unmet needs in metastatic triple-negative breast cancer and how these may be addressed with future clinical trials.
EP. 6: Practical Advice on the Management of TNBC
Before closing out their conversation on metastatic triple-negative breast cancer, expert oncologists share a few clinical pearls on optimizing TNBC management.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC